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syndrome (IBS) was established by colorectal distention (CRD) on post-natal days 8–14.
Responses of the external oblique muscle of the abdomen to CRD were measured to
evaluate the sensitivity of visceral pain in rats. The sensitivity of visceral pain signiﬁcantly
increased in IBS-like rats. Expressions of spinal NR2B subunit and phosphorylated NR2B
subunit signiﬁcantly increased by 50–55% in IBS-like rats when compared with those in
control rats. Ro 25-6981, a selective antagonist of NR2B subunit, has a dose-dependent anti-
allodynic and anti-hyperalgesic effect without causing motor dysfunction in IBS-like rats.
Furthermore, the activation mechanism of the spinal NR2B subunit in chronic visceral pain
was also investigated. Spinal administration of genistein, a speciﬁc inhibitor of tyrosine
kinases, also decreased the visceral pain hypersensitivity of IBS-like rats in a dose-dependent
manner. In addition, the expression of phosphorylated NR2B subunit was decreased after
spinal administration of Ro 25-6981 or genistein in IBS-like rats. In conclusion, tyrosine kinase
activation-induced phosphorylation of NR2B subunit may play a crucial role in central
sensitization of chronic visceral pain.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.Elsevier B.V.
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Table 1 – Mean amplitude of EMG to CRD in rats
(mean7S.E.M.).
EMG to CRD (μV)
40 mmHg 60 mmHg
Control 6 9.0172.40 16.1573.42
IBS 6 18.5975.42n 27.4278.50n
EMG: electromyography; IBS: irritable bowel syndrome; CRD: color-
ectal distention.
n Po0.05 vs. control rats.
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Chronic pain is a major health issue in developed countries.
It can affect up to 20% of the adult population and impose a
severe economic burden (Saito et al., 2002). Currently, there
are more than 100 million patients with chronic pain includ-
ing chronic visceral pain (Shinozaki et al., 2008). Although
chronic inﬂammation and tumors are common pathogenic
factors for chronic visceral pain, there are quite a large
proportion of patients with chronic visceral pain without
pathological alteration, such as irritable bowel syndrome (IBS)
(Xu et al., 2008; Elsenbruch, 2011). Chronic pain remains a
clinical challenge due to its unknown etiology (Longstreth,
2005; Asano et al., 2012).
A proportion of IBS patients display visceral pain hyper-
sensitivity (VPH), which may be the main reason for chronic
abdominal pain or diarrhea of IBS (Farmer and Aziz, 2009).
Central sensitization is thought to play a central role in the
development and maintenance of VPH (Sarkar et al., 2000,
2001). The N-methyl-D-aspartate (NMDA) receptor, an iono-
tropic glutamate receptor, plays a key role in excitatory
synaptic plasticity (Qu et al., 2009). The activation of NMDA
receptors in the spinal dorsal horn is essential to trigger
central sensitization (Bleakman et al., 2006; Woolf, 2007).
Our previous study indicated that the NMDA receptor
antagonist (AP-7) inhibited the increased responses of
lumbosacral neurons to colorectal distention (CRD) in IBS-
like rats (Lin and Al-Chaer, 2005). However, the NMDA
receptor antagonists such as AP-7 or MK-801 are not
approved for treatment of chronic pain, mainly due to its
severe side effects such as motor dysfunction (Chen et al.,
2009).
Subunits composed of NMDAR are classiﬁed as family
NR1, NR2A–D and NR3, in which NR1 is an essential func-
tional subunit, NR2A–NR2D are modulatory subunits, and
the function of NR3 remains unclear (Meguro et al., 1992;
Paoletti and Neyton, 2007). The subtype-speciﬁc drugs may
show greater promise as analgesics for chronic pain due to
their reduced side effects (Boyce et al., 1999; Qu et al., 2009;
Xu et al., 2012). Particularly, spinal cord NR2B subunit is
responsible for the central sensitization (Pedersen and
Gjerstad, 2008). Besides, intrathecal injection of the selective
NR2B receptor antagonist, Ro 25-6981, can dose-dependently
inhibit neuropathic pain without causing motor dysfunction
(Qu et al., 2009). There is growing evidence that there are
some differences between the mechanisms of visceral and
somatic pain (Wesselmann et al., 2009). Our previous study
has discovered an over-expression of the NR2B subunit at
the lumbosacral spinal cord in IBS-like rats (Lin et al., 2008),
but the potential mechanism of its action remains to be
clariﬁed.
In the present study, an IBS-like rat was established by
CRD on post-natal days 8–14 (Lin et al., 2006). Visceral pain
hypersensitivity was evaluated by measuring amplitude of
electromyographic (EMG) to CRD. The expression of spinal
NR2B subunit and phosphorylated NR2B subunit was ana-
lyzed by western blot. Effects of the selective antagonist of
NR2B subunit and the speciﬁc inhibitor of tyrosine kinases on
visceral hypersensitivity were also evaluated.2. Results
2.1. Neonatal CRD resulted in visceral pain
hypersensitivity and enhanced expression of spinal NR2B
subunit in adult rats
Responses of EMG to CRD signiﬁcantly increased in IBS-like
rats (Bonferroni T test, Po0.05, Table 1). Responses of EMG in
IBS-like rats increased by 106% and 69% under 40 and
60 mmHg CRD, respectively, when compared with those in
control rats. These data indicated that neonatal CRD resulted
in visceral pain hypersensitivity in adult rats. Western blot
results showed that expression of spinal NR2B subunit was
signiﬁcantly increased by 55% (from 0.2070.02 to 0.3170.01)
in IBS-like rats as compared with that in control rats (SNK-q-
test, Po0.05, Fig. 1). The expression of spinal NR2B subunit
was not affected by intrathecal injection of Ro 25-6981.2.2. Ro 25-6981 treatment attenuated visceral pain
hypersensitivity in IBS-like rats
Ro 25-6981, a selective NR2B subunit antagonist, was intra-
thecal injected into rats to demonstrate whether the spinal
NR2B subunit plays a role in the development of chronic
visceral pain. No signiﬁcant change was observed at 30 min
after i.t. 150 μg (the maximum dose) Ro 25-6981 in control rats
(Bonferroni T test, P40.05, Fig. 2A). There was no obvious
change between i.t. 25 μg Ro 25-6981 and DMSO in responses
of EMG to 40–60 mmHg CRD in IBS-like rats (Bonferroni T test,
P40.05, Fig. 3A and B). Responses of EMG were decreased by
53% (from 18.5975.42 μV to 8.7372.54 μV ) and 36% (from
27.4278.50 μV to 17.5273.08 μV) under 40 and 60 mmHg CRD
at 30 min after i.t. 75 μg Ro 25-6981, respectively, as compared
with the vehicle in IBS-like rats (Bonferroni T test, Po0.05,
Fig. 3A and B). Responses of EMG were decreased by 77%
(from 18.5975.42 μV to 4.3272.18 μV) under 40 mmHg CRD at
30 min after i.t. 150 μg Ro 25-6981 as compared with the
vehicle in IBS-like rats, and decreased by 64% (from 27.427
8.50 μV to 10.0174.01 μV),under 60 mmHg CRD at 30 min after
i.t. 150 μg Ro 25-6981 (Bonferroni T test, Po0.05, Fig. 3A and B).
Responses of EMG were decreased by 60% (from 22.107
4.77 μV to 8.7372.54 μV) under 40 mmHg CRD and by 48%
(from 33.4775.69 μV to 17.5273.08 μV) under 60 mmHg CRD
at 30 min after i.t. 75 μg Ro 25-6981 as compared with i.t. 25 μg
Ro 25-6981 in IBS-like rats (Bonferroni T test, Po0.05, Fig. 3A
and B). Responses of EMG were decreased by 52% (from
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after i.t. 150 μg Ro 25-6981 as compared with i.t. 75 μg Ro 25-
6981 in IBS-like rats, and decreased by 43% (from
17.5273.08 μV to10.0174.01 μV) under 60 mmHg CRD (Bonfer-
roni T test, Po0.05, Fig. 3A and B). These data suggested that
Ro 25-6981 had a dose-dependent anti-allodynic and anti-
hyperalgesic effect in IBS-like rats. These results suggested
that the visceral pain hypersensitivity in IBS-like rats was
mediated by the NMDA receptor NR2B subunit in the
spinal cord.Fig. 1 – Expression of lumbosacral spinal NR2B-containing
NMDA receptors in rats: (A) the original expression of spinal
NR2B receptor in rats. Western blots for Group IBSþD and
IBSþRo obtained at 30 min after i.t. The β-actin was used as
the loading control and the density of NR2B was expressed
as ratio of β-actin. (B) Statistical chart showed that the
expression level of spinal NR2B receptor signiﬁcantly
increased in IBS-like rats, and the expression level of spinal
NR2B receptor had no changes after i.t. 75 μg Ro 25-6981,
n¼3, respectively. nPo0.05 vs. control rats. NMDA: N-
methyl-D-aspartic acid; IBS: irritable bowel syndrome; D:
DMSO; Ro:Ro 25-6981.
Fig. 2 – Effects of Ro 25-6981 and genistein on EMG in control ra
60 mmHg CRD in control rats and (B) effect of i.t. 1.0 mg geniste
respectively. EMG: electromyography; CRD: colorectal distention2.3. Time course of inhibitory effect of Ro 25-6981 on
chronic visceral pain in IBS-like rats
To further observe the best time and duration of Ro 25-6981
on visceral pain hypersensitivity, we recorded the amplitudets: (A) effect of i.t. 150 μg Ro 25-6981 on EMG under 40 and
in on EMG under 40 and 60 mmHg CRD in control rats, n¼6,
; Ro: Ro 25-6981; G: genistein.
Fig. 3 – Inhibitory effect of Ro 25-6981 on visceral pain
hypersensitivity in IBS-like rats: (A) original response to 40
and 60 mmHg CRD after i.t. Ro 25-6981 in IBS-like rats.
(B) The statistical chart of the amplitude of EMG after i.t. Ro
25-6981 in IBS-like rats. Spinal administration of 75–150 μg
Ro 25-6981 signiﬁcantly inhibited chronic visceral pain in
IBS-like rats, n¼6, respectively. nPo0.05 vs. IBSþDMSO rats.
EMG: electromyography; CRD: colorectal distention; IBS:
irritable bowel syndrome; Ro: Ro 25-6981.
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(75 μg) under 40–60 mmHg CRD in IBS-like rats. The lowest
standardized amplitude of EMG was 7.4773.01 μV and
15.2172.35 μV under 40 and 60 mmHg CRD, respectively, at
30 min after i.t. Ro 25-6981 (75 μg). Responses of EMG to CRD
were basically recovered at 2 h after i.t. Ro 25-6981. Responses
of EMG to CRD were lowered by 60%, 40%, 30%, and 10%
respectively at 30, 60, 90, and 120 min after i.t.75 μg Ro 25-6981
under 40 mmHg CRD, and lowered by 45%, 25%, 1%, and 2%
respectively under 60mmHg CRD in IBS-like rats (Fig. 4A and B).
These results suggested the maximal inhibition was observed
at 30 min after Ro 25-6981 application under either 40 or
60 mmHg CRD in IBS-like rats (Bonferroni T test, Po0.05,
Fig. 4A and B).2.4. Phosphorylation of spinal NR2B subunit was
inhibited by Ro 25-6981 or genistein in IBS-like rats
The effect of genistein, a tyrosine kinase inhibitor, was
investigated to the potential activation mechanism of the
spinal NR2B subunit in central sensitization of chronic
visceral pain. Expression of phosphorylated NR2B subunit
enhanced by 50% (from 0.1970.02 to 0.2970.03) in IBS-like
rats as compared with that in control rats. The expression of
phosphorylated NR2B subunit was decreased by 38% (fromFig. 4 – The time course of inhibitory effect of Ro 25-6981 and ge
the time course of the effect of 75 μg Ro 25-6981 on the amplitu
maximal inhibition was observed at 30 min after Ro 25-6981 app
course of the effect of 0.5 mg genistein on the amplitude of EMG
inhibition was observed at 60 min after genistein application un
nPo0.05 vs. pre-drug. EMG: electromyography; CRD: colorectal d0.2970.03 to 0.1870.02) at 30 min after i.t. Ro 25-6981 (75 μg),
and 31% (from 0.2970.03 to 0.2070.04) at 60 min after i.t.
genistein (0.5 mg), respectively, as compared with i.t. DMSO in
IBS-like rats (SNK-q-test, Po0.05, Fig. 5B). The ratio
(0.9270.08) of normalized pho-NR2B of normalized NR2B in
IBS-like rats was similar with that (0.9670.11) in control rats
(SNK-q-test, P40.05, Fig. 5C). The ratio signiﬁcantly reduced
about 40% (from 0.9370.13 to 0.5670.06) at 30 min after i.t. Ro
25-6981 (75 μg), and 30% (from 0.9370.13 to 0.6570.17) at
60 min after i.t. genistein (0.5 mg), respectively, as compared
with i.t. DMSO in IBS-like rats (SNK-q-test, Po0.05, Fig. 5C).2.5. Tyrosine kinase inhibitor decreased visceral pain
hypersensitivity in IBS-like rats
Results showed that no obvious change was observed after
genistein injection (1.0 mg, the maximum dose) in control
rats (Bonferroni T test, P40.05, Fig. 2B). There was no obvious
change between 0.1 mg genistein and vehicle groups in IBS-
like rats (Bonferroni T test, P40.05, Table 2). Responses of
EMG were decreased by 60% and 34% under 40 and 60 mmHg
CRD at 60 min after i.t. 0.5 mg genistein, respectively, as
compared with vehicle in IBS-like rats (Bonferroni T test,
Po0.05, Table 2). Responses of EMG were decreased by 81%
and 67% under 40 and 60 mmHg CRD at 60 min after i.t.nistein on visceral pain hypersensitivity in IBS-like rats: (A)
de of EMG under 40 and 60 mmHg CRD in IBS-like rats. The
lication under 40–60 mmHg CRD in IBS-like rats. (B) The time
under 40 and 60 mmHg CRD in IBS-like rats. The maximal
der 40–60 mmHg CRD in IBS-like rats, n¼6, respectively.
istention; IBS: irritable bowel syndrome; G: gemistein.
Fig. 5 – Expression of phosphorylation of lumbosacral spinal
NR2B-containing NMDA receptors in rats: (A) the original
expression of phosphorylation of spinal NR2B receptor in
rats. Western blots for Group IBSþD and IBSþRo obtained at
30 min after i.t., and for Group IBSþD and IBSþG obtained at
60 min after i.t. (B) Statistical chart showed that expression
level of phosphorylation of spinal NR2B receptor increased
in IBS-like rats, and signiﬁcantly decreased after i.t. 75 μg Ro
25-6981 or 0.5 mg genistein. (C) The ratio of normalized pho-
NR2B of normalized NR2B in rats. The ratio in IBS-like rats
was similar with that in control rats, but signiﬁcantly
reduced after i.t. 75 μg Ro 25-6981 or 0.5 mg genistein, n¼6,
respectively. nPo0.05 vs. control rats. NMDA: N-methyl-D-
aspartic acid; IBS: irritable bowel syndrome; D: DMSO; Ro:Ro
25-6981; G:genistein.
Table 2 – Inhibitory effect of genistein on EMG to CRD in
IBS-like rats (mean7S.E.M.).
EMG to CRD (μV)
40 mmHg 60 mmHg
IBSþDMSO 6 21.1972.93 27.5673.12
IBSþG 0.1 mg 6 17.9675.49 33.4775.69
IBSþG 0.5 mg 6 8.5273.72n 15.6275.61n
IBSþG 1.0 mg 6 3.9372.18n 8.9874.08n
EMG: electromyography; CRD: colorectal distention; IBS: irritable
bowel syndrome; G: genistein.
n Po0.05 vs. IBSþDMSO rats.
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IBS-like rats. (Bonferroni T test, Po0.05, Table 2). Responses of
EMG were decreased by 53% and under 40 mmHg CRD, and by
53% under 60 mmHg CRD at 60 min after i.t. 0.5 mg genistein
as compared with i.t. 0.1 mg genistein in IBS-like rats (Bon-
ferroni T test, Po0.05, Table 2). Responses of EMG were
decreased by 54% and 43% under 40 and 60 mmHg CRD at
60 min after i.t. 1.0 mg genistein, respectively, as compared
with i.t. 0.5 mg genistein in IBS-like rats (Bonferroni T test,
Po0.05, Table 2). These results suggested that genistein had a
dose-dependent anti-allodynic and anti-hyperalgesic effect,
which implied that tyrosine phosphorylation was the one of
activation mechanisms of the spinal NR2B subunit in central
sensitization of chronic visceral pain.
2.6. Time course of inhibition effect of genistein on chronic
visceral pain in IBS-like rats
The amplitude of EMG was recorded every half an hour
within 2.5 h after i.t. genistein under 40 and 60 mmHg CRD
in IBS-like rats. The lowest amplitude was 8.1675.93 μV and
10.6576.66 μV under 40 and 60 mmHg CRD, respectively, at
60 min after i.t. genistein (0.5 mg). Responses of EMG to CRD
were basically recovered at 2.5 h after i.t. genistein. Responses
of EMG to 40–60 mmHg CRD were lowered by 47–60% and
27–38%, respectively, at 60 and 90min after i.t. 0.5 mg (medium
dose) genistein. These results indicated the best time point
for optimal anti-allodynic effect was observed at 60 min after
i.t. of genistein under either 40 or 60 mmHg CRD in IBS-like
rats (Bonferroni T test, Po0.05, Fig. 4C and D).3. Discussion
We have previously demonstrated that the responses of
lumbosacral neurons to CRD were enhanced in IBS-like rats.
The NMDA receptor antagonist AP-7 inhibited the enhanced
neuronal activity in IBS-like rats (Lin and Al-Chaer, 2005). In
the present study, we further provide new evidence to
demonstrate that the spinal NR2B receptor plays a key role
in the development of visceral hypersensitivity and that
NR2B receptor activities are regulated by tyrosine kinase.
Firstly, the expressions of the spinal NR2B subunit and
phosphorylated NR2B subunit increased in IBS-like rats as
compared with those in control rats. Secondly, enhanced
phosphorylation of spinal NR2B subunit was inhibited after
spinal administration of the selective antagonist of NR2B
subunit, Ro 25-6981, or the tyrosine kinase inhibitor, genis-
tein, in IBS-like rats. Thirdly, visceral pain hypersensitivity
was signiﬁcantly reduced by i.t. Ro 25-6981 or genistein in IBS-
like rats as compared with that in control rats.
3.1. Role of spinal NR2B subunit in central sensitization of
chronic visceral pain
There is growing evidence that there are some similarities
and differences between the mechanisms of visceral and
somatic pain (Wesselmann et al., 2009). Central sensitization
is an important mechanism underlying persistent pain
(Sarkar et al., 2001; Woolf, 2007; Qu et al., 2009). Results
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mediated by spinal NMDA receptor, especially NR2B subunit
(Renno, 1998; Pedersen and Gjerstad, 2008; Hu et al., 2009).
Though central sensitization is also thought to play a central
role in the development and maintenance of visceral pain
(Sarkar et al., 2000, 2001), its mechanism is still unclear. In our
previous studies, the increased responses of lumbosacral
neurons to CRD were inhibited by the NMDA receptor
antagonist, AP-7, in IBS-like rats (Lin and Al-Chaer, 2005). In
addition, the expression of the NR2B subunit at the lumbo-
sacral spinal cord was enhanced in IBS-like rats by the
immunohistochemical method (Lin et al., 2008). In the pre-
sent research, over-expression of spinal NR2B subunit was
further conﬁrmed by Western Blot analysis. Furthermore, the
NR2B subunit antagonist, Ro 25-6981, could dose-dependently
attenuate visceral pain in IBS-like rats. Therefore, we can
infer reasonably that spinal cord NR2B subunit is also
responsible for the central sensitization in visceral pain,
similar to inﬂammatory and neuropathic pain (Qu et al.,
2009; Hu et al., 2009).
Visceral pain hypersensitivity includes allodynia and
hyperalgesia: allodynia implies that an originally non-noxious
stimulation can induce pain; hyperalgesia indicates that an
originally noxious stimulation can induce a supernormal reac-
tion (Al-chaer et al., 2000; Zhuo, 2007; S. Li et al., 2011a; X.Y.
Li et al., 2011b). In our present study, i.t. Ro 25-6981, the NR2B
subunit selective antagonist, attenuated visceral pain by 77%
under 40mmHg CRD (a non-noxious stimulation), and by 64%
under 60mmHg CRD (a noxious stimulation). So, Ro 25-6981
attenuated not only allodynia, but also hyperalgesia in rats with
chronic visceral pain.
Several lines of evidence support the notion that Ro 25-
6981 exerted its analgesic effect via action on the spinal NR2B
subunit in the present study. Firstly, Ro 25-6981 is applied to
the spinal cord by intrathecal injection so that spinal cord is
its target scope in the behavioral experiments. Secondly, Ro
25-6981 is 5000 folds more selective for the heteromeric NR1/
NR2B receptors than the NR1/NR2A receptors (Fischer et al.,
1997). Thirdly, spinal NR2B expression increased by 55%, and
Ro 25-6981 could dose-dependently attenuate visceral pain
hypersensitivity in IBS-like rats. Taken together, our results
provide strong evidence that the spinal NR2B subunit plays
an important role in the central sensitization of chronic
visceral pain. The reason why Ro 25-6981 did not completely
attenuate visceral pain hypersensitivity is likely because of
the low dose of Ro 25-6981 or its complicated mechanisms.
Other signaling molecules such as non-NMDA receptors may
mediate chronic visceral pain (Lin and Al-Chaer, 2005).3.2. Contribution of tyrosine phosphorylation of spinal
NR2B subunit to central sensitization of chronic visceral pain
The NR2B subunit is a membrane glycoprotein with an approx-
imate molecular mass of 170–180 kDa, which is composed of an
extracellular N terminus that binds allosteric inhibitors with an
S1–S2 agonist-binding domain, a transmembrane region that
forms the ion channel and a C-terminal cytoplasmic region that
binds to phosphorylation sites by protein kinase, such as PKC
and tyrosine kinase (Hollmann et al., 1993; Mony et al., 2009).Tyrosine kinase activation-induced phosphorylation of NR2B
subunit contributes to the central sensitization among the
signal transduction pathways (Xiong et al., 1999, Liu et al.,
2004). There is potent evidence that the activation of tyrosine
phosphorylated NR2B in the spinal cord is abolished by a
tyrosine kinase inhibitor, genistein, in inﬂammatory pain (Ali
and Salter, 2001). In agreement with the studies in the inﬂam-
matory hyperalgesia reported by Guo et al. (2002), our results
also show that genistein (i.t.) could inhibit visceral hypersensi-
tivity and block the over-expression of tyrosine phosphorylated
NR2B subunit in spinal cord in IBS-like rats. The above-
mentioned results indicate that there may be a similar activa-
tion mechanism of spinal NR2B between visceral pain and
inﬂammatory pain. Meanwhile, it is reasonable to draw a
conclusion that the tyrosine phosphorylation could be one of
the activation mechanisms of spinal NR2B subunit in the
central sensitization of chronic visceral pain.
The ratio of pho-NR2B in total NR2B apparently increased
in inﬂammatory pain (Xu et al., 2012) and the postoperative
hyperalgesia induced by remifentanil (Gu et al., 2009). Our
results showed the ratio did not signiﬁcantly increase in
IBS-like rats when compared with that in control rats. How-
ever, total NR2B and phosphorylated NR2B in IBS-like rats
signiﬁcantly increased when compared with those in control
rats. It appears that the most of increased NR2B was phos-
phorylated in IBS-like rats, namely the signiﬁcant enhance-
ment of expression level of total NR2B results in apparent
increases in pho-NR2B. We have several reasons to explain
this phenomenon. Firstly, there are some fundamental dif-
ferences between the mechanisms responsible in visceral
and somatic pain (Wesselmann et al., 2009). Secondly, inﬂam-
matory pain and the postoperative hyperalgesia induced by
remifentanil are acute or sub-chronic pain (few days up to 1
month), while the visceral pain established in this present
study is a chronic pain (at least 2 months). Chronic stimula-
tion may result in up-regulating the NR2B subunit. Thus,
there are both similarities and differences in the mechanisms
of visceral and somatic pain.
Visceral pain was attenuated by 77%, 64% respectively
under 40 and 60 mmHg CRD after i.t. Ro 25-6981, 54%, 43%
respectively after i.t. genistein. Genistein did not attenuate
visceral pain hypersensitivity as much as Ro 25-6981 is likely
because that there are other signaling pathways in the
activation mechanism of spinal NR2B subunit. In addition,
NR2B subunit has seven phosphorylation sites for tyrosine
kinase, with its main phosphorylation sites including S1303,
S1323, S1480, Y1252, Y1336, and Y1472 (Nakazawa et al., 2001;
Qiu et al., 2011). In this study, western blot results showed
that expression of Tyr-1472 of NR2B in spinal cord signiﬁ-
cantly enhanced in IBS-like rats as compared with that in
control rats. Thus, spinal NR2B phosphorylation at tyrosine
1472 contributed to spinal sensitization of chronic visceral
pain, which is similar with the results in NMDA-induced
pain hypersensitivity reported by S. Li et al., (2011a).
3.3. The superiority of NR2B subunit for treatment of
chronic visceral pain
Chronic visceral pain of IBS is treated mainly by medications
and acupuncture. However, currently available pharmacological
b r a i n r e s e a r c h 1 5 4 2 ( 2 0 1 4 ) 1 6 7 – 1 7 5 173treatments for IBS show only moderately improved efﬁcacy
over placebo without curing the underlying disease itself
(Drossman et al., 2008; Farmer and Aziz, 2009; Wesselmann
et al., 2009). NMDA receptor antagonist MK-801 has been
shown to signiﬁcantly relieve chronic visceral pain by inhi-
biting spinal sensitization. However, this type of nonspeciﬁc
subunit receptor antagonist may induce severe side effects
such as learning and memory impairment, sensory or moti-
lity disorders, and hyperactivity (Jevtovic-Todorovic et al.,
1998). The good news is that subtype-speciﬁc drugs which
selectively target NR2B subunit-containing receptors may
show greater promise as analgesics for neuropathic pain
due to their reduced side effects (Boyce et al., 1999; Qu
et al., 2009; Xu et al., 2012). The NR2B subunit selective
antagonist, Ro 25-6981, is more selective than MK-801
(Fischer et al., 1997). In our experiment, no signiﬁcant side
effects were observed up to the maximum dose of Ro 25-6981,
which was in conformity with the results in neuropathic pain
reported by Qu et al. (2009).
There are conﬂicting studies on the efﬁcacy of acupunc-
ture treatment for functional visceral pain in patients with
IBS (Lembo et al., 2009; Liu et al., 2009; Shi et al., 2012). In the
experiment, Ro 25-6981 reduced visceral pain by 77% and
64%, respectively, under 40 and 60 mmHg CRD in IBS-like rats.
Cui et al. reported that acupuncture treatment could respec-
tively decrease chronic visceral pain by 45% and 40% under 40
and 60 mmHg CRD in IBS-like rats (Cui et al., 2005). This
shows Ro 25-6981 has a stronger effect than acupuncture
treatment in pain-relief. Thus, the NR2B receptor antagonist,
Ro 25-6981, is demonstrated to be a high-efﬁciency and low-
toxicity candidate for relieving chronic visceral pain.
In summary, our results imply that the increase of visceral
pain hypersensitivity in IBS-like rats was mediated by the
spinal NMDA receptor NR2B subunit. In addition, the under-
lying activation mechanism of the spinal NR2B subunit
appears to be via tyrosine phosphorylation.4. Experimental procedures
4.1. Animals
Male Sprague-Dawley neonatal rats (younger than 5 days)
were provided by the Department of Experimental Animal
Center at Fujian Medical University. The animals were
housed with a nursing adult female rat until they were 25
days old. After separation from the adult female rats, the
weaned male rats were raised for at least 2 months before
surgery and housed six in a cage with access to food and
water ad libitum. The animal experimental procedures were
conducted in accordance with the guidelines of the Interna-
tional Association for the Study of Pain (Zimmermann, 1983).
The experiments were approved by the Animal Care and Use
Committee of Fujian Medical University.
4.2. Animal model of visceral hyperalgesia
In order to investigate mechanisms of pain in IBS sufferers,
we developed a modiﬁed rat model of chronic visceral pain,
based on an IBS model reported by Lin and Al-Chaer (2003).Daily 60 mmHg CRD was performed on neonatal rats begin-
ning 8–14 days after birth (Lin et al., 2006). Compared with the
model reported by Lin and Al-Chaer (a daily pressure of
60 mmHg CRD stimulation at days 8–21 after birth), the model
we established showed a lower mortality and a higher rate of
success. The responses of EMG to CRD in IBS-like rats are
consistent with those reported by Lin and Al-Chaer (2003).
The distention was applied using vascular reconstruction
balloon (length: 20.0 mm; diameter: 2.5 mm) inserted into
the descending colon through the rectum of awake rats.
The balloon was quickly distended with 60 mmHg for 1 min
and then deﬂated and withdrawn. The control rats received
the same procedure except CRD. After the distention stimu-
lus was terminated, the rats were kept until they reached
adulthood (at least 8 weeks old), and then experiments were
performed.
4.3. Assessment of visceral hypersensitivity
Visceral hypersensitivity of rats (8 weeks old) were evaluated
by recording electromyography (EMG) from the external
oblique muscle of abdomen (EOMA) in responses to CRD
stimulation under anesthesia with isoﬂurane by anesthesia
machine (VMR, Matrx, USA). CRD stimulus was applied using
an inﬂatable balloon (constructed from no. 7 latex, 6 cm in
length, which was inﬂated with air overnight before the
experiment) attached to an intravenous line via a T connector
that was also attached to a 10-ml syringe and a sphygmo-
manometer. A collapsed non-distensible balloon was inserted
into the anus and advanced into the colorectum using
glycerol while the animal was anesthetized, 1 cm from the
base of the balloon to the anus. After the balloon was
advanced into the colon, it was secured by taping the
attached tubing to the rat’s tail. Silver bipolar electrodes were
inserted above the inguinal ligament on the side of the
external oblique 1.5 cm away from the midline, and then an
appropriate dose of anesthetic was administered. Generally,
the vaporizer scale was adjusted to about 1 and maintained
the constant dose continuously when evaluating visceral
hypersensitivity of rats, so that the rats were in a state of
light anesthesia. Subjective indicator of light anesthesia is
that experimental rats have no spontaneous activity but have
perception of pain induced by pinching posterior limb using
hemostatic forceps. The balloon was inﬂated to 40 and
60 mmHg for 10 s followed by 4 min rest. In the present
experiment, 40 and 60 mmHg CRD were selected to lower
colorectal stimulation of rats whereas Lin et al. used 20, 40,
60, and 80 mm Hg CRD. The pressure of 40 mmHg CRD is a
non-nociceptive stimulation, and 60 mmHg CRD pressure is a
nociceptive stimulation (Al-Chaer et al., 2000). The magnitude
of EMG activity was measured by a RM6240BD multi-channel
physiological signal acquisition and processing system (the
instrument, made in Chendu, China). (Parameter settings:
high-frequency ﬁltration of 3 kHz, time constant of 0.001,
sampling frequency of 40 Hz, sensitivity of 200 μV, and paper
speed of 200 ms/div.) The software of the system recorded
20 amplitudes during each 10 s distention period, and their
mean amplitude was representative for magnitude of EMG.
In the statistical analysis, data of EMG were derived from
mean amplitude of EMG during each 10 s of distention
b r a i n r e s e a r c h 1 5 4 2 ( 2 0 1 4 ) 1 6 7 – 1 7 5174subtracting the mean baseline amplitude for the 10 s pre-
distention period for each pressure in order to avoid inﬂuence
of baseline before CRD. In order to avoid the interference of
other factors, a single blind operation was adopted in the
experiment. Furthermore, the rats were kept in a quiet
environment, with relative humidity maintained at 40–70%
and room temperature at 23–27 1C.
4.4. Intrathecal catheter implantation
Implantation of intrathecal cannula (i.t.) was performed
under chloral hydrate (0.3 g/kg, i.p.) anesthesia according to
the method of Størkson et al. (1996). Brieﬂy, a PE-10 poly-
ethylene catheter (Becton Dickinson) was implanted between
the L5 and L6 vertebrae to reach the lumbar enlargement of
the spinal cord. The outer part of the catheter was plugged
and ﬁxed onto the skin on closure of the wound. Rats
showing neurological deﬁcits after the catheter implantation
were euthanized. Drugs or vehicle were intrathecally injected
via the implanted catheter in a 10 μl volume of solution
followed by 10 μl of normal saline for ﬂushing. Each injection
lasted at least 5 min, and the needle remained in situ for
2 min before being withdrawn after an injection.
4.5. Western blotting
Equal amounts of protein (50 μg) from the spinal dorsal horn
of rats were separated and electro-transferred onto PVDF
membranes (Invitrogen, USA), which were probed with
mouse anti-NR2B monoclonal antibody (1:500, Abcam, USA),
Rabbit anti-NR2B (pTyr1472) polyclonal antibody (1:1000,
Abcam, USA) and mouse anti-β-actin primary antibody
(1:1000, Abcam, USA). Blots were washed and incubated in
peroxidase-conjugated goat anti-rabbit IgG (1:5000, Abcam,
USA) or goat anti-mouse IgG (1:5000, Abcam, USA). Bands
were visualized using an ECL system.
4.6. Statistical analysis
All data were expressed as mean7S.E.M. One-way repeated
measures analysis of variance (ANOVA) was used to deter-
mine whether there was a signiﬁcant difference in standar-
dized amplitude of EMG between control and IBS-like rat.
After intrathecal injection of compounds, standardized data
were analyzed using two-way repeated measures ANOVA
with Bonferroni post hoc analysis. Western blot results were
examined by one or two-way ANOVA with Student–New-
man–Keuls (SNK) multiple comparisons post-hoc analysis.
Po0.05 was considered to be statistically signiﬁcant.Author contributions
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